Original Publish Date: January 8, 2019
On October 24, 2018, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) was signed into law. It is a broad piece of bipartisan legislation intended to address the national opioid crisis. One of the bills included in the SUPPORT Act is the Eliminating Kickbacks in Recovery Act of 2018 (EKRA).
EKRA creates criminal penalties for any individual who "solicits or receives any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory" or "pays or offers any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a recovery home, clinical treatment facility, or laboratory or in exchange for an individual using the services of that recovery home, clinical treatment facility, or laboratory." Notably, it extends its prohibitions to services covered by a health care benefit program, which includes both government and private payors.
The language of the act is very broad and the term laboratory is not limited to just those laboratories associated with substance abuse services. Instead, laboratory is defined as "a facility for the biological, microbiological, serological, chemical, immuno-hematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings." Therefore, enforcement action under EKRA could potentially reach laboratories outside the scope of substance abuse treatment. Additionally, EKRA seems to implicate engagement of sales and marketing representatives, as such individuals are compensated for inducing referrals.
There are several noteworthy exceptions to EKRA, some of which pull through language included in the federal Anti-Kickback Statute safe harbors and exceptions. Specifically, the act does not apply to the following:
This law appears to be the federal government’s way of addressing the relationships within the substance abuse and clinical laboratory industry that can fall outside the scope of Medicare/Medicaid enforcement (i.e., Stark Law and Anti-Kickback Statute) due to the fact that claims for these types of services often are not submitted to government health care benefit programs and instead are only submitted to private payors. This act is significant in that it appears to create an anti-kickback equivalent that impacts all payors (including private payors). Violation of EKRA is punishable by a fine of up to $200,000 and/or imprisonment of up to ten years for each occurrence.
EKRA is still very new and as a result, the scope of its enforcement is yet to be determined. However, it is important to keep EKRA in mind when structuring arrangements with recovery homes, clinical treatment facilities, and laboratories to ensure that the arrangement complies with the prohibitions specified in the act or, in the alternative, that it falls within one of its exceptions. Existing arrangements should also be reevaluated to assess compliance under the new law. It is recommended that EKRA be closely followed to determine the scope of its impact.
Mr. Cooper provides legal representation to a broad range of hospitals, other healthcare facilities and physician groups across the United States. He has been listed in The Best Lawyers in America for health law for twenty-three consecutive years and selected for inclusion in Ohio Super Lawyers (2005-2015).
Visit the McDonald Hopkins LLC web site at www.mcdonaldhopkins.com.